Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 7

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
40,124   120,469 Recoveries for expected credit losses  (94,912)  (584,415)Depreciation of property, plant and equipment  54,442   40,343 Dividend income  (17,560)  (20,827)Fair value loss/(gain) on investments in equity securities  91,243   (72,884)Loss arising from settlement of supplier contract dispute  -   28,554 Gain on disposal of investments in equity securities  -   (14,298)Operating loss before working capital changes  (1,138,850)  (387,011)         Changes in operating assets and liabilities:        Inventories  173,001   104,767 Trade and other receivables  (368,335)  (2,641)Trade and other payables  (112,559)  (458,424)Advance payment from customer  (84,531)  5,937 Operating lease liabilities  (13,401)  (22,266)Tax (liabilities)/recoverable  (17,304)  50,210 Net cash used in operating activities  (1,561,979)  (709,428)         Cash flows from investing activities:        Acquisition of investments in equity securities  -   (264,768)Dividend income  17,560   20,827 Change in fixed deposits placed with original maturities more than three months  (31,227)  (40,200)Purchase of plant and equipment  (30,511)  (23,778)Proceeds from disposal of investments in equity securities  -   297,678 Proceeds from settlement of supplier contract dispute  -   77,201 Net cash (used in)/generated from investing activities  (44,178)  66,960          Cash flows from financing activities:        (Repayment to)/Advances from Directors  (1,385)  202,344 Cash paid for fractional shares in reverse stock split  (505)  - Net cash (used in)/generated from financing activities  (1,890)  202,344          Foreign currency translation